Rapport Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
-38.94 | -268.1 | -85.47% | 0 | 0% |
| P/S |
|
0 | 55.96 | -100% |
|
|
| P/BV |
|
12.05 | 251.23 | -95.21% |
|
|
| P/FCF |
|
-45.36 | -196.64 | -76.93% |
|
|
| Ev/Ebitda |
|
-46.78 | 12.23 | -482.34% |
|
|
| Ev/S |
|
0 | 457.86 | -100% |
|
|
| Ev/FCF |
|
-53.9 | -232.19 | -76.79% |
|
|
| E/P |
|
-0.0257 | 0.0224 | -214.92% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | -341.3 | -100% | 0 | 0% |
| ROE |
|
-35.09 | 103.63 | -133.86% |
|
|
| ROA |
|
-33.3 | -2.84 | 1073.23% |
|
|
| ROIC |
|
0 | 1.17 | -100% |
|
|
| ROS |
|
0 | -298.77 | -100% |
|
|
| ROCE |
|
-25.64 | -0.0718 | 35610.51% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.0191 | 0.9431 | -102.02% | -0.277 | -93.12% |
| Nеt Debt/Ebitda |
|
0.7142 | 1.03 | -30.33% |
|
|
| Debt/Ratio |
|
0.0047 | 0.1785 | -97.37% |
|
|
| Debt/Equity |
|
0.0311 | 1.56 | -98% |
|
|
| Debt/Net Income |
|
-0.0188 | -1.48 | -98.73% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5195 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.8444 | -100% | ||
| DSI |
|
0 | 0.2147 | -100% |
|
|
| Average dividend growth |
|
0 | 1.27 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.5087 | -100% |
|
|
| Average percentage for payments |
|
0 | 59.63 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5195 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -87.95 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
648.34 | -156.19 | -515.1% | ||
| Growth impulse Net Income in 5 years |
|
635.14 | -172.49 | -468.22% | ||
| Growth impulse FCF in 5 years |
|
1806.78 | -114.74 | -1674.67% | ||
| Growth impulse EPS in 5 years |
|
29.66 | -98.04 | -130.25% |
IP Score
3.47/10
